Umifenovir in hospitalized moderate to severe COVID-19 patients: A randomized clinical trial

INTRODUCTION: The effectiveness of umifenovir against COVID-19 is controversial; therefore, clinical trials are crucial to evaluate its efficacy. METHODS: The study was conducted as a single-center, randomized, open-label clinical trial. Eligible moderate-severe hospitalized patients with confirmed...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Int Immunopharmacol
Egile Nagusiak: Alavi Darazam, Ilad, Shokouhi, Shervin, Mardani, Masoud, Pourhoseingholi, Mohamad Amin, Rabiei, Mohammad Mahdi, Hatami, Firouze, Shabani, Minoosh, Moradi, Omid, Gharehbagh, Farid Javandoust, Irvani, Seyed Sina Naghibi, Amirdosara, Mahdi, Hajiesmaeili, Mohammadreza, Rezaei, Omidvar, Khoshkar, Ali, Lotfollahi, Legha, Gachkar, Latif, Dehbsneh, Hadiseh Shabanpour, Khalili, Negar, Soleymaninia, Azam, Kusha, Akram Hoseyni, Shoushtari, Maryam Taleb, Torabinavid, Parham
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Elsevier B.V. 2021
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC8270750/
https://ncbi.nlm.nih.gov/pubmed/34273635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.intimp.2021.107969
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak